Pharmacokinetics and Safety of Fosfluconazole after Single Intravenous Bolus Injection in Healthy Male Japanese Volunteers

Journal of Clinical Pharmacology

Volumn 44, Issue 3, 2004, Pages 284-292

  Sobue, Satoshi ^a   Sekiguchi, Kaneo ^a   Shimatani, Katsuyoshi ^a   Tan, Keith ^b  

^a PFIZER INC   (United States)

^b PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

Author keywords

Antifungal drug; Fluconazole; Fosfluconazole; Pharmacokinetics; Safety

Indexed keywords

ANTIFUNGAL AGENT; FLUCONAZOLE; FOSFLUCONAZOLE; PRODRUG; UNCLASSIFIED DRUG;

ADULT; AREA UNDER THE CURVE; ARTICLE; BIOTRANSFORMATION; BOLUS INJECTION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIARRHEA; DISTRIBUTION VOLUME; DRUG ELIMINATION; DRUG EXCRETION; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; DRUG URINE LEVEL; ECG ABNORMALITY; HUMAN; HUMAN EXPERIMENT; INJECTION PAIN; JAPAN; MALE; NORMAL HUMAN; SIDE EFFECT; SINGLE BLIND PROCEDURE; SINGLE DRUG DOSE;

ADULT; ANTIFUNGAL AGENTS; AREA UNDER CURVE; COHORT STUDIES; CROSS-OVER STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; ELECTROCARDIOGRAPHY; FLUCONAZOLE; HALF-LIFE; HUMANS; INJECTIONS, INTRAVENOUS; MALE; PHOSPHORIC ACID ESTERS; PRODRUGS; SINGLE-BLIND METHOD; TIME FACTORS;

EID: 1242343727     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1177/0091270003262799     Document Type: Article

References (12)

1. Marriot MS, Richardson K: The discovery and mode of action of fluconazole, in: Fromtling RA (ed.), Recent Trends in the Discovery, Development and Evaluation of Antifungal Agents. Barcelona, Spain: JR Prous Science Publishers, 1987;81-92.
2. Richardson K, Cooper K, Marriott MS, Tarbit MH, Troke PF, Whittle PJ: Discovery of fluconazole, a novel antifungal agent. Rev Infect Dis 1990;12(Suppl. 3):S267-S271.
3. Rex JH, Walsh TJ, Sobel JD, Filler SG, Pappas PG, Dismukes WE, et al: Practice guidelines for the treatment of candidiasis. Infectious Diseases Society of America. Clin Infect Dis 2000;30:662-678.
4. Goa KL, Barradell LB: Fluconazole: an update of its pharmacodynamic and pharmacokinetic properties and therapeutic use in major superficial and systemic mycoses in immunocompromised patients. Drugs 1995;50:658-690.
5. Troke PF: Large-scale multicentre study of fluconazole in the treatment of hospitalised patients with fungal infections. Multicentre European Study Group. Eur J Clin Microbiol Infect Dis 1997;16:287-295.
6. Bentley A, Butters M, Green SP, Learmonth WJ, Macrae JA, Morland MC, et al: The discovery and process development of a commercial route to the water soluble prodrug, fosfluconazole. Org Process Res Dev 2002;6:109-112.
7. Coding Symbols for the Thesaurus of Adverse Reaction Terms (COSTART). 5th ed. Rockville, MD: U.S. Food and Drug Administration, 1995.
8. SAS Institute: SAS/SAT User's Guide, version 6.09. 4th ed. Cary, NC: SAS Institute, 1994.
9. Rowland M, Tozer TN: Clinical Pharmacokinetics: Concepts and Applications. 3rd ed. Baltimore: Williams & Wilkins, 1995.
10. Shiba K, Saito A, Miyahara T: Safety and pharmacokinetics of single oral and intravenous doses of fluconazole in healthy subjects. Clin Ther 1990;12:206-215.
11. Brammer KW, Farrow PR, Faulkner JK: Pharmacokinetics and tissue penetration of fluconazole in humans. Rev Infect Dis 1990; 12(Suppl. 3):S318-S326.
12. Humphrey MJ, Jevons S, Tarbit MH: Pharmacokinetic evaluation of UK-49,858, a metabolically stable triazole antifungal drug, in animals and humans. Antimicrob Agents Chemother 1985;28:648-653.